Cargando…

Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung cancer

OBJECTIVES: This study aimed to explore the novel biomarkers for immune checkpoint inhibitor (ICI) responses in non‐small cell lung cancer (NSCLC) by integrating genomic profiling, tumor mutational burden (TMB), and expression of programmed death receptor 1 ligand (PD‐L1). MATERIALS AND METHODS: Tum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Yunfei, Lei, Youming, Liu, Li, Zhang, Shiyue, Wang, Wenjing, Zhao, Juan, Zhao, Songhui, Dong, Xiaowei, Yao, Ming, Wang, Kai, Zhou, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982619/ https://www.ncbi.nlm.nih.gov/pubmed/33655698 http://dx.doi.org/10.1002/cam4.3649

Ejemplares similares

Comprehensive genomic profiling of high‐grade serous ovarian carcinoma from Chinese patients identifies co‐occurring mutations in the Ras/Raf pathway with TP53
por: Zhong, Fangfang, et al.
Publicado: (2019)

Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer
por: Zang, Yuan‐sheng, et al.
Publicado: (2019)

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‐L1 expression in cancer patients
por: Nikanjam, Mina, et al.
Publicado: (2019)

PEG3 mutation is associated with elevated tumor mutation burden and poor prognosis in breast cancer
por: Zhang, Min, et al.
Publicado: (2020)

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
por: Zhu, Jason, et al.
Publicado: (2018)

An miRNA signature associated with tumor mutation burden in endometrial cancer
por: Zhou, Hongyu, et al.
Publicado: (2020)

Integrated bioinformatics analysis identified MTHFD1L as a potential biomarker and correlated with immune infiltrates in hepatocellular carcinoma
por: Chen, Junhui, et al.
Publicado: (2021)

Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer
por: Qiu, Xin, et al.
Publicado: (2023)

Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD‐L1 immunotherapy
por: Wu, Chih‐Hsun, et al.
Publicado: (2019)

Screening and identification of LMNB1 and DLGAP5, two key biomarkers in gliomas
por: Zhou, Ding, et al.
Publicado: (2021)

Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy
por: Cui, Xin, et al.
Publicado: (2020)

Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy
por: Wang, Peipei, et al.
Publicado: (2021)

Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report
por: Xie, Xiao-Hong, et al.
Publicado: (2023)

Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients
por: Vanderwalde, Ari, et al.
Publicado: (2018)

Prostasin regulates PD-L1 expression in human lung cancer cells
por: Chen, Li-Mei, et al.
Publicado: (2021)

Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor
por: Chu, Ling-Yu, et al.
Publicado: (2021)

CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
por: Xiao, Minglu, et al.
Publicado: (2022)

Baseline monocyte and its classical subtype may predict efficacy of PD-1/PD-L1 inhibitor in cancers
por: Shao, Yilin, et al.
Publicado: (2021)

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
por: Chan, T A, et al.
Publicado: (2019)

Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy
por: Hsu, Melinda L, et al.
Publicado: (2022)

PD‐L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer
por: Ji, Xiaoyu, et al.
Publicado: (2021)

Harnessing neutrophil plasticity for HCC immunotherapy
por: Ramon-Gil, Erik, et al.
Publicado: (2023)

Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report
por: Mou, Haibo, et al.
Publicado: (2018)

Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair‐Deficient Prostate Cancer
por: Sena, Laura A., et al.
Publicado: (2020)

Obesity diminishes response to PD-1-based immunotherapies in renal cancer
por: Boi, Shannon K, et al.
Publicado: (2020)

Tryptophan metabolism and disposition in cancer biology and immunotherapy
por: Badawy, Abdulla A.-B.
Publicado: (2022)

Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy
por: Zhang, Yixiao, et al.
Publicado: (2020)

Comprehensive analysis of the effect of rs2295080 and rs2536 polymorphisms within the mTOR gene on cancer risk
por: Qi, Guang-Hui, et al.
Publicado: (2020)

Comprehensive Genomic Profiling of NF2-Mutated Kidney Tumors Reveals Potential Targets for Therapy
por: Hacking, Sean M, et al.
Publicado: (2023)

Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
por: Wang, Zhengyi, et al.
Publicado: (2020)

Combined ARHGEF6 and Tumor Mutational Burden may serve as a potential biomarker for immunotherapy of lung adenocarcinoma
por: Tong, Li, et al.
Publicado: (2023)

Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy
por: Gao, Hannan, et al.
Publicado: (2020)

Tissue-derived exosome proteomics identifies promising diagnostic biomarkers for esophageal cancer
por: Rao, Dingyu, et al.
Publicado: (2023)

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
por: Helgadottir, Hildur, et al.
Publicado: (2020)

Comprehensive Analysis of Ferroptosis Regulators in Lung Adenocarcinomas Identifies Prognostic and Immunotherapy-Related Biomarkers
por: Sun, Sijin, et al.
Publicado: (2021)

Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes
por: Lou, Jiaying, et al.
Publicado: (2021)

Comprehensive analysis of DTYMK in pan-cancer and verification in lung adenocarcinoma
por: Zhang, Yue, et al.
Publicado: (2022)

Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
por: Hu, Weixian
Publicado: (2019)

High number of PD‐1 positive intratumoural lymphocytes predicts survival benefit of cytokine‐induced killer cells for hepatocellular carcinoma patients
por: Chang, Boyang, et al.
Publicado: (2018)

Identification of CXCL5 expression as a predictive biomarker associated with response and prognosis of immunotherapy in patients with non‐small cell lung cancer
por: Deng, Jie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5fhrtrc7uh7seocfv9k3raluda